Clinical Research Directory
Browse clinical research sites, groups, and studies.
Liquid BiOpsy, Lung and Colon Cancer in AndaluciA
Sponsor: Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Summary
The objective of the LOLA Project is to analyse the impact of adopting xF liquid biopsy panel, in the real world of the Andalusian Health Public System in terms of impact on clinical practice and cost through the assessment of clinical impact, duration of turnaround time (TAT) of xF test vs standard of care and the analysis of resource utilisation.
Official title: Clinical Implementation of Liquid Biopsy in Cancer Through Next Generation Sequencing (NGS) Panels in the Andalusian Public Health System
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2024-08-01
Completion Date
2026-07-30
Last Updated
2025-05-30
Healthy Volunteers
No
Interventions
xF Tempus assay
The blood will be collected and sent to Tempus Labs using the standard sample collection kit containing all the necessary elements to guarantee shipment to Tempus Labs. Two Streck tubes with 8.5mL of blood per tube will be sent to Tempus Labs. The ctDNA isolation and automatic library preparation will be performed using TEMPUS technology (Finkel et al 2021). The NGS analyses will be developed using the xF Tempus assay. This assay involves a panel with hybrid gene capture that detects actionable oncologic targets in four variant classes: single-nucleotide variants (SNVs), insertions/deletions (indels), copy number variants (CNVs), and gene rearrangements. The NGS sequencing is performed using NovaSeq 6000Dx Sequencing System (Illumina, Inc) equipment, according to Tempus protocols. (Finkel et al 2021).
Locations (1)
Centre for Genomics and Oncological Research - Pfizer - University of Granada - Andalusian Regional Government (GENyO)
Granada, Andalusia, Spain